BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld Asia
Home
» Sanofi Files for Lixisenatide OK In Japan, Awaits EU Decision
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Sanofi Files for Lixisenatide OK In Japan, Awaits EU Decision
June 13, 2012
By
Cormac Sheridan
No Comments
With its diabetes drug lixisenatide already undergoing regulatory review in Europe, Sanofi SA disclosed Monday, during the American Diabetes Association (ADA) meeting in Philadelphia, that it has now filed for regulatory approval in Japan.
BioWorld Asia